MarketWatch (blog) | InterMune lung drug passes trial, shares nearly triple Reuters It is also approved in Japan, South Korea, China, India, Argentina and Mexico. IPF is an irreversible condition that leads to progressive loss of lung function due to scarring, which hinders a lung's ability to absorb oxygen. InterMune said it expected ... InterMune shares more than double on tests for lung-disease treatment InterMune more than doubles on lung-drug study InterMune hits 2-year high on US Esbriet study |
